All News

Rage Bio secures AU$29 million in Series A funding. Appoints Siro Perez as Chief Executive Officer & Edwin Tucker as Chief Medical and Development Officer.

Melbourne, Australia – RAGE Biotech Pty Ltd (‘Rage Bio’), a company developing precision splice-switching oligonucleotide (SSO) therapeutics to fight chronic inflammatory disease, has raised $A29 million in its Series A funding round. Rage Bio has also announced two key executive appointments, naming Dr Siro Perez as Chief Executive Officer and Dr. Edwin Tucker as Chief Medical and Development Officer. The funding round was led by IP Group Australia and Hostplus, with continu

Rage Bio

Nov 13, 20254 min read